Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-06-15 / Clin. Cancer Res. 2011 Jun;17(12):3884-91Improvement of dendritic cell therapy in glioblastoma multiforme WHO 4 by Newcastle disease virus.
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2011-06-06 / J Clin Oncol 29: 2011 (suppl; abstr 2508)Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 4670)Pilot immunotherapy trial in high-risk pediatric sarcomas.
/in Dendritic Cells, Soft Tissue Sarcoma /von 2011-06-05 / J Clin Oncol 29: 2011 (suppl; abstr 9541)Melanoma patients treated with dendritic cell vaccination, interleukin-2, and metronomic cyclophosphamide: Results from a phase II trial.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr e13084)A dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 2533)Survival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
/in Colorectal Cancer, Dendritic Cells, International Publications /von 2011-06-04 / J Clin Oncol 29: 2011 (suppl; abstr 3557)Immuno-cell therapy with antecedent surgery has superior actuarial survival to immuno-cell therapy without antecedent surgery for advanced cancers
/in Dendritic Cells, International Publications /von 2011-06-03 / Cancer Immunol. Immunother. 2011 Oct;60(10):1397-403Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-18
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de